2-hydroxyglutaric acid

Cross Reference

There are no associated biomedical information in the current reference collection.

Current reference collection contains 1586 references associated with 2-hydroxyglutaric acid in LipidPedia. Due to lack of full text of references or no associated biomedical terms are recognized in our current text-mining method, we cannot extract any biomedical terms related to diseases, pathways, locations, functions, genes, lipids, and animal models from the associated reference collection.

Users can download the reference list at the bottom of this page and read the reference manually to find out biomedical information.

Here are additional resources we collected from PubChem and MeSH for 2-hydroxyglutaric acid

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with 2-hydroxyglutaric acid

MeSH term MeSH ID Detail
Tyrosinemias D020176 2 associated lipids
Canavan Disease D017825 2 associated lipids
Hyperoxaluria D006959 3 associated lipids
Phenylketonurias D010661 7 associated lipids
Metabolic Diseases D008659 12 associated lipids
Total 5

PubChem Associated disorders and diseases

PubChem Biomolecular Interactions and Pathways

NCBI Entrez Crosslinks

All references with 2-hydroxyglutaric acid

Download all related citations
Per page 10 20 50 100 | Total 448
Authors Title Published Journal PubMed Link
Boiangiu CD et al. Sodium ion pumps and hydrogen production in glutamate fermenting anaerobic bacteria. 2005 J. Mol. Microbiol. Biotechnol. pmid:16645308
Reitman ZJ and Yan H Isocitrate dehydrogenase 1 and 2 mutations in cancer: alterations at a crossroads of cellular metabolism. 2010 J. Natl. Cancer Inst. pmid:20513808
Wen H et al. Metabolomic comparison between cells over-expressing isocitrate dehydrogenase 1 and 2 mutants and the effects of an inhibitor on the metabolism. 2015 J. Neurochem. pmid:25251602
Owens WE and Okun MS Dystonia, tremor, and parkinsonism in a 54 year old man with 2-hydroxyglutaric aciduria. 2004 J. Neurol. Neurosurg. Psychiatry pmid:15314137
Bleeker FE et al. Recent advances in the molecular understanding of glioblastoma. 2012 J. Neurooncol. pmid:22270850
Pope WB et al. Non-invasive detection of 2-hydroxyglutarate and other metabolites in IDH1 mutant glioma patients using magnetic resonance spectroscopy. 2012 J. Neurooncol. pmid:22015945
Paravati AJ et al. Radiotherapy and temozolomide for newly diagnosed glioblastoma and anaplastic astrocytoma: validation of Radiation Therapy Oncology Group-Recursive Partitioning Analysis in the IMRT and temozolomide era. 2011 J. Neurooncol. pmid:21181233
Yang I and Liau LM American Association for Cancer Research Genetics and Biology of Brain Cancers 2009, December 13-15, 2009, San Diego, CA. 2010 J. Neurooncol. pmid:20714783
Kim H et al. In-Vivo Proton Magnetic Resonance Spectroscopy of 2-Hydroxyglutarate in Isocitrate Dehydrogenase-Mutated Gliomas: A Technical Review for Neuroradiologists. 2016 Sep-Oct Korean J Radiol pmid:27587950
Pollyea DA et al. 2-Hydroxyglutarate in IDH mutant acute myeloid leukemia: predicting patient responses, minimal residual disease and correlations with methylcytosine and hydroxymethylcytosine levels. 2013 Leuk. Lymphoma pmid:22680765
Chaturvedi A et al. Pan-mutant-IDH1 inhibitor BAY1436032 is highly effective against human IDH1 mutant acute myeloid leukemia in vivo. 2017 Leukemia pmid:28232670
Chaturvedi A et al. Enantiomer-specific and paracrine leukemogenicity of mutant IDH metabolite 2-hydroxyglutarate. 2016 Leukemia pmid:27063596
Tefferi A et al. IDH mutations in primary myelofibrosis predict leukemic transformation and shortened survival: clinical evidence for leukemogenic collaboration with JAK2V617F. 2012 Leukemia pmid:21912393
Tefferi A et al. IDH1 and IDH2 mutation studies in 1473 patients with chronic-, fibrotic- or blast-phase essential thrombocythemia, polycythemia vera or myelofibrosis. 2010 Leukemia pmid:20508616
Patnaik MM et al. WHO-defined 'myelodysplastic syndrome with isolated del(5q)' in 88 consecutive patients: survival data, leukemic transformation rates and prevalence of JAK2, MPL and IDH mutations. 2010 Leukemia pmid:20485371
Tefferi A Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1. 2010 Leukemia pmid:20428194
D'Alò F et al. Similarities and differences between therapy-related and elderly acute myeloid leukemia. 2011 Mediterr J Hematol Infect Dis pmid:22220249
Heux S et al. Cofactor engineering in Saccharomyces cerevisiae: Expression of a H2O-forming NADH oxidase and impact on redox metabolism. 2006 Metab. Eng. pmid:16473032
Willquist K et al. Reassessment of hydrogen tolerance in Caldicellulosiruptor saccharolyticus. 2011 Microb. Cell Fact. pmid:22189215
Vogel RF et al. Genomic analysis reveals Lactobacillus sanfranciscensis as stable element in traditional sourdoughs. 2011 Microb. Cell Fact. pmid:21995419
Johannessen TA et al. Rapid Conversion of Mutant IDH1 from Driver to Passenger in a Model of Human Gliomagenesis. 2016 Mol. Cancer Res. pmid:27430238
Li F et al. NADP(+)-IDH Mutations Promote Hypersuccinylation that Impairs Mitochondria Respiration and Induces Apoptosis Resistance. 2015 Mol. Cell pmid:26585387
Ma S et al. L2hgdh Deficiency Accumulates l-2-Hydroxyglutarate with Progressive Leukoencephalopathy and Neurodegeneration. 2017 Mol. Cell. Biol. pmid:28137912
Ricoult SJ et al. Sterol Regulatory Element Binding Protein Regulates the Expression and Metabolic Functions of Wild-Type and Oncogenic IDH1. 2016 Mol. Cell. Biol. pmid:27354064
Struys EA et al. D-2-hydroxyglutaric aciduria in three patients with proven SSADH deficiency: genetic coincidence or a related biochemical epiphenomenon? 2006 Mol. Genet. Metab. pmid:16442322
Das AM Regulation of the mitochondrial ATP-synthase in health and disease. 2003 Mol. Genet. Metab. pmid:12809636
Tarhonskaya H et al. Non-enzymatic chemistry enables 2-hydroxyglutarate-mediated activation of 2-oxoglutarate oxygenases. 2014 Nat Commun pmid:24594748
Chaumeil MM et al. Non-invasive in vivo assessment of IDH1 mutational status in glioma. 2013 Nat Commun pmid:24019001
Guilhamon P et al. Meta-analysis of IDH-mutant cancers identifies EBF1 as an interaction partner for TET2. 2013 Nat Commun pmid:23863747
Ansó E et al. The mitochondrial respiratory chain is essential for haematopoietic stem cell function. 2017 Nat. Cell Biol. pmid:28504706
Intlekofer AM et al. L-2-Hydroxyglutarate production arises from noncanonical enzyme function at acidic pH. 2017 Nat. Chem. Biol. pmid:28263965
Chan SM et al. Isocitrate dehydrogenase 1 and 2 mutations induce BCL-2 dependence in acute myeloid leukemia. 2015 Nat. Med. pmid:25599133
Choi C et al. 2-hydroxyglutarate detection by magnetic resonance spectroscopy in IDH-mutated patients with gliomas. 2012 Nat. Med. pmid:22281806
Tyrakis PA et al. S-2-hydroxyglutarate regulates CD8+ T-lymphocyte fate. 2016 Nature pmid:27798602
Flavahan WA et al. Insulator dysfunction and oncogene activation in IDH mutant gliomas. 2016 Nature pmid:26700815
Saha SK et al. Mutant IDH inhibits HNF-4α to block hepatocyte differentiation and promote biliary cancer. 2014 Nature pmid:25043045
Lu C et al. IDH mutation impairs histone demethylation and results in a block to cell differentiation. 2012 Nature pmid:22343901
Koivunen P et al. Transformation by the (R)-enantiomer of 2-hydroxyglutarate linked to EGLN activation. 2012 Nature pmid:22343896
Dang L et al. Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. 2010 Nature pmid:20559394
Dang L et al. Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. 2009 Nature pmid:19935646
Jafari-Khouzani K et al. Volumetric relationship between 2-hydroxyglutarate and FLAIR hyperintensity has potential implications for radiotherapy planning of mutant IDH glioma patients. 2016 Neuro-oncology pmid:27382115
Nagashima H et al. Diagnostic value of glutamate with 2-hydroxyglutarate in magnetic resonance spectroscopy for IDH1 mutant glioma. 2016 Neuro-oncology pmid:27154922
de la Fuente MI et al. Integration of 2-hydroxyglutarate-proton magnetic resonance spectroscopy into clinical practice for disease monitoring in isocitrate dehydrogenase-mutant glioma. 2016 Neuro-oncology pmid:26691210
Waitkus MS et al. Isocitrate dehydrogenase mutations in gliomas. 2016 Neuro-oncology pmid:26188014
Juratli TA et al. Accumulation of 2-hydroxyglutarate is not a biomarker for malignant progression in IDH-mutated low-grade gliomas. 2013 Neuro-oncology pmid:23410661
Lazovic J et al. Detection of 2-hydroxyglutaric acid in vivo by proton magnetic resonance spectroscopy in U87 glioma cells overexpressing isocitrate dehydrogenase-1 mutation. 2012 Neuro-oncology pmid:23090985
Luchman HA et al. An in vivo patient-derived model of endogenous IDH1-mutant glioma. 2012 Neuro-oncology pmid:22166263
Scott JG et al. Production of 2-hydroxyglutarate by isocitrate dehydrogenase 1-mutated gliomas: an evolutionary alternative to the Warburg shift? 2011 Neuro-oncology pmid:21784755
Choi C et al. A comparative study of short- and long-TE ¹H MRS at 3 T for in vivo detection of 2-hydroxyglutarate in brain tumors. 2013 NMR Biomed pmid:23592268
Kahmen A et al. Foliar delta(15)N values characterize soil N cycling and reflect nitrate or ammonium preference of plants along a temperate grassland gradient. 2008 Oecologia pmid:18414899